Trengestone

Trengestone
Clinical data
Trade names	Reteroid, Retroid, Retrone
Other names	Ro 4-8347; Triengestone; 1,6-Didehydro-6-chlororetroprogesterone; 6-Chloro-9β-10α-pregna-1,4,6-triene-3,20-dione
Routes of; administration	By mouth
Drug class	Progestogen; Progestin
ATC code	None;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	≥41–46% (based on urinary excretion)
Metabolism	Liver
Metabolites	• 20α-Dihydrotrengestone
Elimination half-life	• Trengestone: very short; • 20α-DHTG: 8–14 hours
Excretion	Urine: 41–46%; Feces: 30% (unchanged)
Identifiers
	IUPAC name (8S,9S,10R,13S,14S,17S)-17-acetyl-6-chloro-10,13-dimethyl-8,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one;
CAS Number	5192-84-7;
PubChem CID	56840930;
ChemSpider	28475379;
UNII	VY6S496SVX;
ChEBI	CHEBI:135458;
ChEMBL	ChEMBL2107518;
CompTox Dashboard (EPA)	DTXSID101023713 ;
ECHA InfoCard	100.023.617
Chemical and physical data
Formula	C21H25ClO2
Molar mass	344.88 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)C=C[C@]34C)Cl)C;
	InChI InChI=1S/C21H25ClO2/c1-12(23)15-4-5-16-14-11-19(22)18-10-13(24)6-8-21(18,3)17(14)7-9-20(15,16)2/h6,8,10-11,14-17H,4-5,7,9H2,1-3H3/t14-,15+,16-,17-,20+,21+/m0/s1; Key:USXVMPAWZOOYDE-HGUQNLGYSA-N;

Trengestone, sold under the brand names Reteroid, Retroid, and Retrone, is a progestin medication which was formerly used to treat menstrual disorders but is now no longer marketed. It is taken by mouth.

Side effects of trengestone include headache, fatigue, and breast tenderness among others. Trengestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It is not androgenic or estrogenic.

Trengestone was introduced for medical use in 1974. It is no longer available.